These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 16211545)
1. Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Del Giudice I; Morilla A; Osuji N; Matutes E; Morilla R; Burford A; Maravelaki S; Owusu-Ankomah K; Swansbury J; A'Hern R; Brito-Babapulle V; Catovsky D Cancer; 2005 Nov; 104(10):2124-32. PubMed ID: 16211545 [TBL] [Abstract][Full Text] [Related]
2. ZAP-70 protein expression and CD38 positivity in B-cell chronic lymphocytic leukemia. Ertault-Daneshpouy M; Noguera ME; Gisselbrecht C; Haddad A; Brice P; Marolleau JP; Soulier J; Mounier N Clin Adv Hematol Oncol; 2008 Jan; 6(1):55-63. PubMed ID: 18322442 [TBL] [Abstract][Full Text] [Related]
3. Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method. Gachard N; Salviat A; Boutet C; Arnoulet C; Durrieu F; Lenormand B; Leprêtre S; Olschwang S; Jardin F; Lafage-Pochitaloff M; Penther D; Sainty D; Reminieras L; Feuillard J; Béné MC; Haematologica; 2008 Feb; 93(2):215-23. PubMed ID: 18223290 [TBL] [Abstract][Full Text] [Related]
4. Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70). Schade U; Bock O; Vornhusen S; Jäger A; Büsche G; Lehmann U; Kreipe H Hum Pathol; 2006 Sep; 37(9):1153-61. PubMed ID: 16938520 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. D'Arena G; Tarnani M; Rumi C; Vaisitti T; Aydin S; De Filippi R; Perrone F; Pinto A; Chiusolo P; Deaglio S; Malavasi F; Laurenti L Am J Hematol; 2007 Sep; 82(9):787-91. PubMed ID: 17534928 [TBL] [Abstract][Full Text] [Related]
7. Zap-70 and CD38 as predictors of IgVH mutation in CLL. Cruse JM; Lewis RE; Webb RN; Sanders CM; Suggs JL Exp Mol Pathol; 2007 Dec; 83(3):459-61. PubMed ID: 17931624 [TBL] [Abstract][Full Text] [Related]
8. Significance of zeta-associated protein (ZAP-70) and CD38 expression in chronic lymphocytic leukemia. el-Sharnouby JA; el-Shakankiri AA; Hendy OM; Ahmed LM; Taha AM Egypt J Immunol; 2006; 13(2):69-84. PubMed ID: 18689273 [TBL] [Abstract][Full Text] [Related]
9. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Schroers R; Griesinger F; Trümper L; Haase D; Kulle B; Klein-Hitpass L; Sellmann L; Dührsen U; Dürig J Leukemia; 2005 May; 19(5):750-8. PubMed ID: 15759031 [TBL] [Abstract][Full Text] [Related]
10. ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor. Zanotti R; Ambrosetti A; Lestani M; Ghia P; Pattaro C; Remo A; Zanetti F; Stella S; Perbellini O; Prato G; Guida G; Caligaris-Cappio F; Menestrina F; Pizzolo G; Chilosi M Leukemia; 2007 Jan; 21(1):102-9. PubMed ID: 17082778 [TBL] [Abstract][Full Text] [Related]
11. Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia. Molica S; Digiesi G; Battaglia C; Cutrona G; Antenucci A; Molica M; Giannarelli D; Sperduti I; Gentile M; Morabito F; Ferrarini M Eur J Haematol; 2010 Oct; 85(4):314-20. PubMed ID: 20546021 [TBL] [Abstract][Full Text] [Related]
12. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression. Matthews C; Catherwood MA; Morris TC; Kettle PJ; Drake MB; Gilmore WS; Alexander HD Eur J Haematol; 2006 Oct; 77(4):309-17. PubMed ID: 16856923 [TBL] [Abstract][Full Text] [Related]
13. Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: A methodological approach. Passam F; Tachynopoulou V; Skoumi D; Tsompanakou A; Stavropoulos-Giokas A; Vadikolia C; Anagnostopoulos A; Paterakis G Ann Hematol; 2006 Nov; 85(11):795-805. PubMed ID: 16871389 [TBL] [Abstract][Full Text] [Related]
14. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers. Schwarz J; Mikulenková D; Cermáková M; Polanská V; Michalová K; Marinov I; Campr V; Ransdorfová S; Marková J; Pavlistová L; Brezinová J; Sajdová J; Sponerová D; Volková Z; Benesová K; Cermák J; Vítek A; Cetkovský P Neoplasma; 2006; 53(3):219-25. PubMed ID: 16652191 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. Grever MR; Lucas DM; Dewald GW; Neuberg DS; Reed JC; Kitada S; Flinn IW; Tallman MS; Appelbaum FR; Larson RA; Paietta E; Jelinek DF; Gribben JG; Byrd JC J Clin Oncol; 2007 Mar; 25(7):799-804. PubMed ID: 17283363 [TBL] [Abstract][Full Text] [Related]
16. The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma. Soma LA; Craig FE; Swerdlow SH Hum Pathol; 2006 Feb; 37(2):152-9. PubMed ID: 16426914 [TBL] [Abstract][Full Text] [Related]
17. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. Crespo M; Bosch F; Villamor N; Bellosillo B; Colomer D; Rozman M; Marcé S; López-Guillermo A; Campo E; Montserrat E N Engl J Med; 2003 May; 348(18):1764-75. PubMed ID: 12724482 [TBL] [Abstract][Full Text] [Related]